blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1322383

EP1322383 - METHODS OF THERAPY FOR B-CELL MALIGNANCIES USING ANTAGONIST ANTI-CD40 ANTIBODIES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  30.03.2007
Database last updated on 04.11.2024
Most recent event   Tooltip12.12.2008Lapse of the patent in a contracting state
New state(s): CY		published on 14.01.2009  [2009/03]
Applicant(s)For all designated states
Novartis Vaccines and Diagnostics, Inc.
4560 Horton Street
Emeryville, CA 94608 / US
[2007/04]
Former [2006/21]For all designated states
CHIRON CORPORATION
4560 Horton Street
Emeryville, California 94608-2916 / US
Former [2003/27]For all designated states
CHIRON CORPORATION
4560 Horton Street
Emeryville California 94608-2916 / US
Inventor(s)01 / CHU, Keting
Chiron Corporation P.O. Box 8097
Emeryville, CA 94622-8097 / US
02 / MASUOKA, Lorianne
Chiron Corporation P.O. Box 8097
Emeryville, CA 94622-8097 / US
 [2003/27]
Representative(s)Duckworth, Timothy John
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
[N/P]
Former [2003/27]Duckworth, Timothy John
J.A. Kemp & Co., 14 South Square, Gray's Inn
London WC1R 5JJ / GB
Application number, filing date01977428.002.10.2001
[2003/27]
WO2001US30963
Priority number, dateUS20000237556P02.10.2000         Original published format: US 237556 P
[2003/27]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO0228481
Date:11.04.2002
Language:EN
[2002/15]
Type: A2 Application without search report 
No.:EP1322383
Date:02.07.2003
Language:EN
The application published by WIPO in one of the EPO official languages on 11.04.2002 takes the place of the publication of the European patent application.
[2003/27]
Type: B1 Patent specification 
No.:EP1322383
Date:24.05.2006
Language:EN
[2006/21]
Type: B9 Corrected patent specification 
No.:EP1322383
Date:06.09.2006
[2006/36]
Search report(s)International search report - published on:EP06.03.2003
ClassificationIPC:A61P35/00, A61K39/395, // C07K16:28
[2003/27]
CPC:
C07K16/2878 (EP,US); A61P1/00 (EP); A61P1/04 (EP);
A61P1/16 (EP); A61P17/06 (EP); A61P19/02 (EP);
A61P25/00 (EP); A61P29/00 (EP); A61P35/00 (EP);
A61P35/02 (EP); A61P35/04 (EP); A61P37/00 (EP);
A61P37/02 (EP); A61P37/06 (EP); A61P37/08 (EP);
A61P43/00 (EP); A61P7/02 (EP); A61P7/04 (EP);
A01K2217/05 (EP,US); A61K2039/505 (EP,US); C07K2317/21 (EP,US);
C12N2799/026 (EP,US) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2003/27]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
RONot yet paid
SINot yet paid
TitleGerman:VERFAHREN ZUR THERAPIE VON B-ZELLMALIGNITÄTEN UNTER VERWENDUNG VON ANTAGONISTISCHEN ANTIKÖRPERN GEGEN CD40[2003/27]
English:METHODS OF THERAPY FOR B-CELL MALIGNANCIES USING ANTAGONIST ANTI-CD40 ANTIBODIES[2003/27]
French:METHODES THERAPEUTIQUES POUR LUTTER CONTRE LES CELLULES B MALIGNES AVEC DES ANTICORPS ANTAGONISTES ANTI-CD40[2005/49]
Former [2003/27]METHODES THERAPEUTIQUES POUR LUTTER CONTRE LES CELLULES B MALIGNES
Entry into regional phase22.04.2003National basic fee paid 
22.04.2003Designation fee(s) paid 
22.04.2003Examination fee paid 
Examination procedure28.02.2002Request for preliminary examination filed
International Preliminary Examining Authority: EP
22.04.2003Amendment by applicant (claims and/or description)
22.04.2003Examination requested  [2003/27]
22.01.2004Despatch of a communication from the examining division (Time limit: M06)
27.07.2004Reply to a communication from the examining division
09.02.2005Despatch of a communication from the examining division (Time limit: M06)
05.08.2005Reply to a communication from the examining division
15.11.2005Communication of intention to grant the patent
22.03.2006Fee for grant paid
22.03.2006Fee for publishing/printing paid
Divisional application(s)EP06005656.1  / EP1717251
Opposition(s)27.02.2007No opposition filed within time limit [2007/18]
Fees paidRenewal fee
22.04.2003Renewal fee patent year 03
25.10.2004Renewal fee patent year 04
07.10.2005Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT24.05.2006
BE24.05.2006
CY24.05.2006
FI24.05.2006
NL24.05.2006
TR24.05.2006
DK24.08.2006
SE24.08.2006
GR25.08.2006
ES04.09.2006
IE02.10.2006
LU02.10.2006
PT24.10.2006
MC31.10.2006
[2009/03]
Former [2008/37]AT24.05.2006
BE24.05.2006
FI24.05.2006
NL24.05.2006
TR24.05.2006
DK24.08.2006
SE24.08.2006
GR25.08.2006
ES04.09.2006
IE02.10.2006
LU02.10.2006
PT24.10.2006
MC31.10.2006
Former [2008/20]AT24.05.2006
BE24.05.2006
FI24.05.2006
NL24.05.2006
DK24.08.2006
SE24.08.2006
GR25.08.2006
ES04.09.2006
IE02.10.2006
PT24.10.2006
MC31.10.2006
Former [2007/50]AT24.05.2006
BE24.05.2006
FI24.05.2006
NL24.05.2006
DK24.08.2006
SE24.08.2006
ES04.09.2006
IE02.10.2006
PT24.10.2006
MC31.10.2006
Former [2007/48]AT24.05.2006
BE24.05.2006
FI24.05.2006
IT24.05.2006
NL24.05.2006
DK24.08.2006
SE24.08.2006
ES04.09.2006
IE02.10.2006
PT24.10.2006
MC31.10.2006
Former [2007/37]AT24.05.2006
BE24.05.2006
FI24.05.2006
IT24.05.2006
NL24.05.2006
DK24.08.2006
SE24.08.2006
ES04.09.2006
PT24.10.2006
MC31.10.2006
Former [2007/19]AT24.05.2006
BE24.05.2006
FI24.05.2006
NL24.05.2006
DK24.08.2006
SE24.08.2006
ES04.09.2006
PT24.10.2006
Former [2007/13]AT24.05.2006
BE24.05.2006
FI24.05.2006
DK24.08.2006
SE24.08.2006
ES04.09.2006
PT24.10.2006
Former [2007/12]AT24.05.2006
FI24.05.2006
DK24.08.2006
SE24.08.2006
ES04.09.2006
PT24.10.2006
Former [2007/10]AT24.05.2006
FI24.05.2006
DK24.08.2006
SE24.08.2006
ES04.09.2006
Former [2006/52]AT24.05.2006
FI24.05.2006
SE24.08.2006
ES04.09.2006
Former [2006/51]FI24.05.2006
SE24.08.2006
ES04.09.2006
Former [2006/50]SE24.08.2006
ES04.09.2006
Former [2006/48]SE24.08.2006
Cited inInternational search[A]WO9634096  (CELL GENESYS INC [US]) [A] 1-17 * claims 1,14,17,18,24,25 *;
 [X]  - P. KARLSSON ET AL., "Selection of human single chain antibodies against CD40.", IMMUNOLOGY LETTERS, Amsterdam, The Netherlands, (200009), vol. 73, no. 2-3, page 161, XP001073504 [X] 1-17 * abstract 358 *
 [A]  - D. LONGO ET AL, "Inhibition of human B-cell lymphoma growth by soluble recombinant human CD40 ligand (Meeting abstract).", THE FASEB JOURNAL, Bethesda, MD, USA, (1995), vol. 9, no. 3, page A205, XP002215207 [A] 1-17 * abstract 1195 *
ExaminationEP0945465
    - JOURNAL OF IMMUNOLOGY, vol. 164, pages 2200 - 2206
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.